Figure 2

Kaplan–Meier plots of PFS and OS according to KRAS, NRAS, BRAF and PIK3CA gene status. A) The median PFS was 5.8 months (95% CI, 4.8–6.7) among patients with all wild-type tumors (n = 56) and was 2.2 months (1.9–2.5) among those with mutations in KRAS codons 61 or 146, BRAF, NRAS or PIK3CA (n = 10). Differences in PFS between patients with all wild-type tumors and those with mutations in KRAS codons 61 or 146, BRAF, NRAS, or PIK3CA were statistically significant (HR, 3.38; 95% CI, 1.65–6.93; P = 0.001). B) The median OS was 17.7 months (95% CI, 1.1–34.3) among patients with all wild-type tumors (n = 56) and was 5.2 months (3.8–6.6) among those with mutations in KRAS codons 61 or 146, BRAF, NRAS or PIK3CA (n = 10). Differences in OS values between patients with all wild-type tumors and those with mutations in KRAS codons 61 or 146, BRAF, NRAS or PIK3CA were statistically significant (HR, 4.94; 95% CI, 2.12–11.5; P < 0.001).